Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
|
|
CATALYST PHARMACEUTICALS, INC. (CPRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/22/2021 |
GN
| Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program |
| 03/15/2021 |
GN
| Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update |
| 03/04/2021 |
GN
| Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021 |
| 02/22/2021 |
GN
| Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021 |
| 01/06/2021 |
GN
| Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update |
| 11/09/2020 |
GN
| Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update |
| 11/02/2020 |
GN
| Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020 |
| 10/19/2020 |
GN
| Catalyst Pharmaceuticals Announces Filing of Patent Infringement Actions Against Jacobus Pharmaceuticals and PantherRx |
| 10/06/2020 |
GN
| Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse® |
| 09/29/2020 |
GN
| Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal |
| 08/26/2020 |
GN
| KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada's Decision to Overlook Firdapse® Data Exclusivity |
| 08/11/2020 |
GN
| Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for "Methods of Administering 3,4-Diaminopyridine" |
| 08/06/2020 |
GN
| Catalyst Pharmaceuticals' Firdapse® (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMS |
| 08/03/2020 |
GN
| Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders |
| 08/03/2020 |
GN
| Catalyst Pharmaceuticals to Hold Second Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 11th, 2020 |
| 07/31/2020 |
GN
| Catalyst Pharmaceuticals Comments on Magistrate Judge's Report and Recommendation in its Lawsuit against the FDA |
| 06/23/2020 |
GN
| Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer |
| 06/01/2020 |
GN
| Catalyst Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference |
| 05/11/2020 |
GN
| Catalyst Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update |
| 04/08/2020 |
GN
| Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities |
| 03/16/2020 |
GN
| Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update |
| 03/10/2020 |
GN
| Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020 |
| 02/27/2020 |
GN
| Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020 |
| 02/26/2020 |
GN
| Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference |
| 01/06/2020 |
GN
| Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs |
| 11/26/2019 |
GN
| Catalyst Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference |
| 11/12/2019 |
GN
| Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update |
| 11/11/2019 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX |
| 11/01/2019 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX |
| 10/31/2019 |
GN
| Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019 |
| 10/30/2019 |
GN
| Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS) |
| 09/25/2019 |
GN
| Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference |
| 09/23/2019 |
GN
| Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources |
| 09/13/2019 |
GN
| Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock |
|
|
|